Abstract

Abstract Background Endoscopic sleeve gastroplasty (ESG) is emerging as an innovative approach to treating obesity. It provides a bridge between surgical and medical treatments for obesity. Nevertheless, the majority of reports on ESG originate from Western countries, and there is a lack of data from Asian nations. This study aims to share our pioneering experience with this novel technique in Asia. Method We enrolled obese patients with a BMI greater than 27 kg/m2 who were at least 20 years old. Endoscopic sleeve gastroplasty (ESG) was conducted following a comprehensive pre-operative assessment. Following the procedure, patients were scheduled for regular outpatient department (OPD) follow-up appointments at 7 days, 1 month, 2 months, 3 months, and then every 3 months up to 18 months post-operation. Body weight and any adverse events were documented during each follow-up visit. Results A total of 49 obese patients were enrolled in this study. Our findings demonstrate that ESG can be safely integrated into a conventional bariatric surgery center, with a learning curve observed after 10 cases in this study. In our series, the results showed that total body weight loss (TBWL) reached 7% at one month, 9% at three months, 14% at six months, 16% at 12 months, and 18.6% at 18 months. No adverse events or complications were reported in the study; however, five patients experienced procedure failures. Four of these patients underwent a repeat ESG, while one patient opted for surgical intervention. Conclusion Endoscopic sleeve gastroplasty can be utilized in Asian countries, and the effectiveness of weight loss has proven to be satisfactory.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call